Tag: global anti epileptic drugs market

North America to continue to lead the anti-epileptic drugs market – GMI Research

North America to continue to lead the anti-epileptic drugs market – GMI Research

The global Anti-Epileptic Drugs market was valued at USD 3,323.7 million in 2017 and is projected to reach USD 4,458.1 million by 2025, growing at a CAGR of 3.8% during 2018–2025. The major factors driving the anti-epileptic drugs market is the rising awareness about epilepsy, new drug approvals, and drug structure advancements in Anti-Epileptic Drugs industry are likely to drive the growth of the global Anti-Epileptic Drugs market in near future.

Furthermore, advancements in medication management and healthcare services with the increasing number of drug approvals across the globe have led to the burgeoning market growth of Anti-Epileptic Drugs market.

Request Sample Brochure  : https://tinyurl.com/y776x8ar

Valproic Acid drug segment is expected to dominate global Anti-Epileptic Drugs market during the forecast period. In 2017, about one-fourth of the market share was held by Valproic Acid drug in the component segment. However, the highest growth rate is expected to be witnessed by the Lacosamide component segment during the forecast period owing to the increase in usage in the treatment of partial-onset seizures.

“Players are investing a lot in developing and introducing anti-epileptic drugs. For instance, On January 2017, Novartis drug Votubia got approval from EU. This drug will be used for the treatment of refractory partial-onset seizures in patients with TSC. Further, it is foreseen with the growing awareness about the disease and government initiatives the anti-epileptic drugs market will witness significant growth in the emerging markets of Asia-Pacific in the coming 4-5 years .”
—-GMI Research

Based on geography, North America held the largest share in the market in 2017 because of growing awareness about the disease and treatment available, increasing number of rehabs and surgical centers in the region and exponential increase in the epilepsy population. In addition, there has been a rise in the number of approved anti- epileptic drugs. Europe is the second largest region for Anti-Epileptic Drugs market and is expected to grow at a moderate rate during the forecast period.

Buy Report @ https://tinyurl.com/y776x8ar

Key takeaways:
•    In 2017, the Valproic Acid drug type held about one-fourth of the market share.
•    Abbott Laboratories, Cephalon, Inc, Sunovion Pharmaceuticals, and Valeant Pharmaceuticals are the leading players.
•    Lacosamide drug type is anticipated to grow at the highest rate during the forecast period from 2018 to 2025.
•    North America region occupied maximum revenue share in the global Anti-Epileptic Drugs market in 2017.

Some of the key players operating in global Anti-Epileptic Drugs market include Abbott Laboratories, Cephalon, Inc, Sunovion Pharmaceuticals, Valeant Pharmaceuticals International, Sanofi S.A, UCB Pharma Ltd, GlaxoSmithKline plc, Johnson & Johnson, Novartis, AG, Pfizer Inc among others.

The global Anti-Epileptic Drugs market has been segmented on the basis of spectrum type, the market comprises of Narrow and Broad Spectrum. The drug type includes Phenytoin, Phenobarbital, Carbamazepine, Oxcarbazepine, Gabapentin, Pregabalin, Lacosamide, Vigabatrin, Valproic Acid, Lamotrigine, Topiramate, Zonisamide, Levetiracetam, Clonazepam, Rufinamide.

The research report “global Anti-Epileptic Drugs market” provides in-depth analysis of the Anti-Epileptic Drugs market, globally, based on spectrum type, drug type and major geographies for the forecast period from 2018 to 2025. The report highlights the major market drivers propelling the growth as well as challenges faced by the market participants. The research report provides market size and forecast for Anti-Epileptic Drugs market. The report also analyses the competitive landscape, major players and their strategies in 2018. The competitive landscape section of the report captures and highlights the recent developments in the market.

For more details, browse the Table of Contents: https://www.gmiresearch.com/report/global-anti-epileptic-drugs-market-opportunities-forecast-by-spectrum-type-share-trends-industry-report.html

Contact

Sarah Nash
Level 1, The Chase Carmanhall Road,
Sandyford Industrial Estate,
Dublin D18 Y3X2, Ireland
U.S Office +1 860 881 2270
Europe Office +353 1 442 8820
Email: enquiry@gmiresearch.com
Advertisements
Global Anti-Epileptic Drugs Market Opportunities & Forecast (2018-2025)-GMI Research

Global Anti-Epileptic Drugs Market Opportunities & Forecast (2018-2025)-GMI Research

Global Anti-Epileptic Drugs Market, By Spectrum Type (Narrow Spectrum and Broad Spectrum), By Drug (Phenytoin, Phenobarbital, Carbamazepine, Oxcarbazepine, Gabapentin, Pregabalin, Lacosamide, Vigabatrin, Valproic Acid, Lamotrigine, Topiramate, Zonisamide, Levetiracetam, Clonazepam, Rufinamide) and Geography – Opportunities & Forecast, 2018-2025

The global Anti-Epileptic Drugs market was valued at USD 3,323.7 million in 2017 and is projected to reach USD 4,458.1 million by 2025, growing at a CAGR of 3.8% during 2018–2025.

Figure 1: Global Anti-Epileptic Drugs Market Revenue, 2018–2025 (USD Million)

Source: GMI Research

The antiepileptic drug can also be known as an anti-seizure drug, developed for the asymptomatic and idiopathic treatment of epilepsy and seizures. Antiepileptic drugs can also be used for the treatment of neuropathic pain. Causes of epilepsy seizures are not defined or undetermined. However major factors involved include brain injury, stroke, and substance use disorders. Treatment of epilepsy, antiepileptic drugs or medicines (AEDs) are prescribed, preference is made depending on the age of the patient, type of seizures to be treated, and which part of the brain is involved. Moreover, alcoholism, smoking, dietary habits, and rising geriatric population are the major factor driving the antiepileptic drugs market.

Request Sample Brochure  : https://tinyurl.com/y776x8ar

Based on Drugs, Valproic Acid (salt) is anticipated to lead the market during 2018–2025
The valporic Acid segment is expected to hold maximum share in the market during the forecast period due to effective drug structure and usage in most type of seizures. However, the highest growth rate is predicted to be exhibited by Lacosamide drug during the forecast period owing to surging adoption of Anti-Epileptic Drugs market among healthcare professionals and patients due to its homogenous structure. Additionally, the wide availability of technically advanced Anti-Epileptic Drugs diagnosis and treatment and rising demand for home-based Anti-Epileptic Drugs treatment are likely to push the growth of global Anti-Epileptic Drugs market in the forecast years.

Figure 2: Global Anti-Epileptic Drugs Market Revenue, by Region, 2017

Source: GMI Research

North America held the largest share in the global Anti-Epileptic Drugs market in 2017 owing to the growing social awareness, social acceptance, awareness among the population and government and private inclination on Anti-Epileptic Drugs issues. Rest of the World is predicted to be the attractive regional market in global Anti-Epileptic Drugs market and is likely to show the maximum growth in the next few years.

Various notable players operating in global Anti-Epileptic Drugs market include Abbott Laboratories, Cephalon, Inc, Sunovion Pharmaceuticals, Valeant Pharmaceuticals International, Sanofi S.A, UCB Pharma Ltd, GlaxoSmithKline plc, Johnson & Johnson, Novartis, AG, Pfizer Inc among others.

The global Anti-Epileptic Drugs market has been segmented on the basis of spectrum type, drug type, and key geographies. Based on spectrum type, the market comprises of Narrow Spectrum and Broad Spectrum. The drug type includes Phenytoin, Phenobarbital, Carbamazepine, Oxcarbazepine, Gabapentin, Pregabalin, Lacosamide, Vigabatrin, Valproic Acid, Lamotrigine, Topiramate, Zonisamide, Levetiracetam, Clonazepam, Rufinamide

The research report “global Anti-Epileptic Drugs market” provides in-depth analysis of the Anti-Epileptic Drugs market, globally, based on spectrum type, drug type and major geographies for the forecast period from 2018 to 2025. The report highlights the major market drivers propelling the growth as well as challenges faced by the market participants. The research report provides market size and forecast for Anti-Epileptic Drugs market. The report also analyses the competitive landscape, major players and their strategies in 2018. The competitive landscape section of the report captures and highlights the recent developments in the market.

Key questions answered in this research report:
1-    At what pace is the Anti-Epileptic Drugs market growing worldwide? What will be the growth trend in the future?
2-    What are the key drivers and restraints in the current market? What will be the impact of drivers and restraints in the coming years?
3-    What are the regional revenue and forecast breakdowns? Which are the major regional revenue pockets for growth in global Anti-Epileptic Drugs market?
4-    What are the various application areas and how they are poised to grow?

For Sample Pages & Detailed Report Description Click  @   https://www.gmiresearch.com/report/global-anti-epileptic-drugs-market-opportunities-forecast-by-spectrum-type-share-trends-industry-report.html

Table of Contents (TOC)

1.    Executive Summary

2.    Introduction    
2.1.    Study Objectives
2.2.    Market Definition
2.2.1.     Market Covered
2.2.2.    Geographical Coverage
2.2.3.    Study Years & Currency
2.3.    Market Stakeholders
2.4.    Key Questions this Study will Answer
2.5.    GMI Research’s Approach & Methodology

3.    Global Anti-Epileptic Drugs Market – Overview   
3.1.    Introduction         `
3.2.    Market Segmentation
3.3.    Pipeline Analysis
3.4.    Drivers
3.5.    Restraints
3.6.    Trends
4.    Global Anti-Epileptic Drugs Market Revenue Forecast till 2025

5.    Global Anti-Epileptic Drugs Market by Spectrum Revenue Forecast till 2025  
5.1.    Narrow Spectrum
5.2.    Broad Spectrum
6.    Global Anti-Epileptic Drugs Market by Drug Revenue Forecast till 2025
6.1.    Phenytoin
6.2.    Phenobarbital
6.3.    Carbamazepine
6.4.    Oxcarbazepine
6.5.    Gabapentin
6.6.    Pregabalin
6.7.    Lacosamide
6.8.    Vigabatrin
6.9.    Valproic Acid
6.10.    Lamotrigine
6.11.    Topiramate
6.12.    Zonisamide
6.13.    Levetiracetam
6.14.    Clonazepam
6.15.    Rufinamide
7.    Global Anti-Epileptic Drugs Market by Geography Revenue Forecast till 2025

7.1.    North America Anti-Epileptic Drugs Market Revenue Forecast till 2025 (Option 1: 25% customization)
7.1.1.    North America Anti-Epileptic Drugs Market Revenue by Spectrum Forecast till 2025
7.1.1.1.    Narrow Spectrum
7.1.1.2.    Broad Spectrum

7.1.2.    North America Anti-Epileptic Drugs Market by drug Revenue Forecast till 2025
7.1.2.1.    Phenytoin
7.1.2.2.    Phenobarbital
7.1.2.3.    Carbamazepine
7.1.2.4.    Oxcarbazepine
7.1.2.5.    Gabapentin
7.1.2.6.    Pregabalin
7.1.2.7.    Lacosamide
7.1.2.8.    Vigabatrin
7.1.2.9.    Valproic Acid
7.1.2.10.    Lamotrigine
7.1.2.11.    Topiramate
7.1.2.12.    Zonisamide
7.1.2.13.    Levetiracetam
7.1.2.14.    Clonazepam
7.1.2.15.    Rufinamide.

7.2.    Europe Anti-Epileptic Drugs Market Revenue Forecast till 2025
7.2.1.    Europe Anti-Epileptic Drugs Market by Spectrum Revenue Forecast till 2025 (Option 2: 25% customization)
7.2.1.1.    Narrow Spectrum
7.2.1.2.    Broad Spectrum

7.2.2.    Europe Anti-Epileptic Drugs Market by Drug Revenue Forecast till 2025
7.2.2.1.    Phenytoin
7.2.2.2.    Phenobarbital
7.2.2.3.    Carbamazepine
7.2.2.4.    Oxcarbazepine
7.2.2.5.    Gabapentin
7.2.2.6.    Pregabalin
7.2.2.7.    Lacosamide
7.2.2.8.    Vigabatrin
7.2.2.9.    Valproic Acid
7.2.2.10.    Lamotrigine
7.2.2.11.    Topiramate
7.2.2.12.    Zonisamide
7.2.2.13.    Levetiracetam
7.2.2.14.    Clonazepam
7.2.2.15.    Rufinamide.

7.3.    Asia-Pacific Anti-Epileptic Drugs Market Revenue Forecast till 2025
7.3.1.    Asia-Pacific Anti-Epileptic Drugs Market by Spectrum Revenue Forecast till 2025 (Option 3: 25% customization)
7.3.1.1.    Narrow Spectrum
7.3.1.2.    Broad Spectrum

7.3.2.    Asia-Pacific Anti-Epileptic Drugs Market by Drug Revenue Forecast till 2025
7.3.2.1.    Phenytoin
7.3.2.2.    Phenobarbital
7.3.2.3.    Carbamazepine
7.3.2.4.    Oxcarbazepine
7.3.2.5.    Gabapentin
7.3.2.6.    Pregabalin
7.3.2.7.    Lacosamide
7.3.2.8.    Vigabatrin
7.3.2.9.    Valproic Acid
7.3.2.10.    Lamotrigine
7.3.2.11.    Topiramate
7.3.2.12.    Zonisamide
7.3.2.13.    Levetiracetam
7.3.2.14.    Clonazepam
7.3.2.15.    Rufinamide.

7.4.    Rest of the World Anti-Epileptic Drugs Market Revenue Forecast till 2025
7.4.1.    Rest of the World Anti-Epileptic Drugs Market by Spectrum Revenue Forecast till 2025 (Option 4: 25% customization)
7.4.1.1.    Narrow Spectrum
7.4.1.2.    Broad Spectrum

7.4.2.    Rest of the World Anti-Epileptic Drugs Market by Drug Revenue Forecast till 2025
7.4.2.1.    Phenytoin
7.4.2.2.    Phenobarbital
7.4.2.3.    Carbamazepine
7.4.2.4.    Oxcarbazepine
7.4.2.5.    Gabapentin
7.4.2.6.    Pregabalin
7.4.2.7.    Lacosamide
7.4.2.8.    Vigabatrin
7.4.2.9.    Valproic Acid
7.4.2.10.    Lamotrigine
7.4.2.11.    Topiramate
7.4.2.12.    Zonisamide
7.4.2.13.    Levetiracetam
7.4.2.14.    Clonazepam
7.4.2.15.    Rufinamide.

8.    Competitive Landscape        
8.1.    Industry Attractiveness
8.2.    Porter 5 Analysis
8.3.    Major players and their key strategies
8.4.    Company Share Analysis

9.    Company Profiles (Option 5: 25% Customization – Profiles of 5 Additional Companies of your Choice)
9.1.    Abbott Laboratories
9.1.1.    Company Overview
9.1.2.    Financials
9.1.3.    Recent Developments
9.2.    Cephalon, Inc
9.2.1.    Company Overview
9.2.2.    Financials
9.2.3.    Recent Developments
9.3.    Sunovion Pharmaceuticals
9.3.1.    Company Overview
9.3.2.    Financials
9.3.3.    Recent Developments
9.4.    Valeant Pharmaceuticals International
9.4.1.    Company Overview
9.4.2.    Financials
9.4.3.    Recent Developments
9.5.    Sanofi S.A
9.5.1.    Company Overview
9.5.2.    Financials
9.5.3.    Recent Developments
9.6.    UCB Pharma Ltd
9.6.1.    Company Overview
9.6.2.    Financials
9.6.3.    Recent Developments
9.7.    GlaxoSmithKline plc
9.7.1.    Company Overview
9.7.2.    Financials
9.7.3.    Recent Developments
9.8.    Johnson & Johnson
9.8.1.    Company Overview
9.8.2.    Financials
9.8.3.    Recent Developments
9.9.    Novartis AG
9.9.1.    Company Overview
9.9.2.    Financials
9.9.3.    Recent Developments
9.10.    Pfizer Inc
9.10.1.    Company Overview
9.10.2.    Financials
9.10.3.    Recent Developments

10.    About GMI Research

Buy Report @ https://tinyurl.com/y776x8ar

Related Report :

Global Drugs of Abuse Testing Market by Product Type (Instruments and Consumables), By Drug Type (Psychostimulants, Narcotic, Hallucinogens, Sedatives and Others), By Technique Type (Immunoassay, Chromatography and Rapid Testing), By End-User (Hospitals, Diagnostic Laboratories, Forensic Laboratories, Government and Private Departments and Others) and by Geography – Opportunities & Forecast, 2018-2025

About US

GMI Research is a market research and consulting firm which provides research-based solutions to business executives and investment professionals so that they can make right business & investment decisions faster based on real facts. We help business leaders through independent fact-based insight, ensuring their business achieve success by beating the competition.

GMI Research leverages its industry expertise and experience to identify the industry trends, big opportunities and potential growth areas across industries. Our Syndicated reports provide actionable insights and covers industry trends, market drivers & restraints, macroeconomics factors, market estimates & forecasts, competitive landscape etc. which helps our clients to strengthen its market position by deploying specific strategies and actions that will lead to higher growth. 

Our Customized Research (Market Intelligence and Competitive Intelligence) Offerings

Our clients rely on us for the range of our services to give them the intelligence they need to act decisively. GMI Research offers in-depth market and competitive intelligence solutions by leveraging its industry knowledge and experience to provide accurate insights with a complete picture of the market and competition. To know more about our product offering click on the below link:https://www.gmiresearch.com/productservices/marketcompetitiveintelligence.html

Our Company Profile Solution

Company Profiles provide an insight on competitors, customers, and potential suppliers. We at GMI Research understands that the standard or on shelf company profiles provides little help when it comes to business decision making as it doesn’t cover the information required by the clients.

We have developed a range of company profiles solution to meet our client’s specific business requirements irrespective of their role and the industry they operate in. Our company profiles solutions fit into our client’s business requirements because it provides our client’s with a broader choice of profiles: https://www.gmiresearch.com/productservices/companyprofiles.html

Contact – Sarah Nash

Level 1, The Chase Carmanhall Road,
Sandyford Industrial Estate,
Dublin D18 Y3X2, Ireland

U.S Office +1 860 881 2270
Europe Office +353 1 442 8820

Email: sales@gmiresearch.com